Candel Therapeutics, Inc. (CADL): Total Assets
$125.19M
As of 2025-12-31
$208.15M
As of 2026-06-30
+17.2%
3-year compound annual growth
+26.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $125.19M | +17.2% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $106.87M | +159.4% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $41.20M | -47.0% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $77.69M | -12.9% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $89.20M | +133.0% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $38.28M | n/a | 2022-03-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | 2025-12-31 | $125.19M | +17.2% |
| Acumen Pharmaceuticals, Inc. (ABOS) | 2025-12-31 | $122.83M | -48.6% |
| Kalaris Therapeutics, Inc. (KLRS) | 2025-12-31 | $121.74M | n/m |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $130.40M | n/m |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | $130.94M | -37.5% |
| Palisade Bio, Inc. (PALI) | 2025-12-31 | $134.34M | n/m |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $116.37M | -15.6% |
| Zura Bio Ltd (ZURA) | 2025-12-31 | $113.95M | -36.5% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
Compare CADL, ABOS, KLRS, PTHS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗